Compare Biocon with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs STRIDES PHARMA SCIENCE - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON STRIDES PHARMA SCIENCE BIOCON /
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 32.1 42.1 76.3% View Chart
P/BV x 3.8 2.0 194.9% View Chart
Dividend Yield % 0.3 0.2 103.9%  

Financials

 BIOCON    STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    BIOCON
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
BIOCON /
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs7071,147 61.7%   
Low Rs554642 86.3%   
Sales per share (Unadj.) Rs91.9317.2 29.0%  
Earnings per share (Unadj.) Rs16.77.8 213.0%  
Cash flow per share (Unadj.) Rs24.225.1 96.5%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.2 70.9%  
Book value per share (Unadj.) Rs101.6274.3 37.1%  
Shares outstanding (eoy) m600.0089.50 670.4%   
Bonus / Rights / Conversions -ESOP-  
Price / Sales ratio x6.92.8 243.3%   
Avg P/E ratio x37.7114.0 33.1%  
P/CF ratio (eoy) x26.135.7 73.1%  
Price / Book Value ratio x6.23.3 190.2%  
Dividend payout %6.025.5 23.5%   
Avg Mkt Cap Rs m378,33080,058 472.6%   
No. of employees `0006.12.5 244.6%   
Total wages/salary Rs m11,6534,341 268.5%   
Avg. sales/employee Rs Th8,994.311,325.8 79.4%   
Avg. wages/employee Rs Th1,900.71,731.4 109.8%   
Avg. net profit/employee Rs Th1,635.3280.1 583.9%   
INCOME DATA
Net Sales Rs m55,14428,394 194.2%  
Other income Rs m1,444941 153.5%   
Total revenues Rs m56,58829,334 192.9%   
Gross profit Rs m15,8833,965 400.5%  
Depreciation Rs m4,4781,540 290.7%   
Interest Rs m7091,962 36.1%   
Profit before tax Rs m12,1401,403 865.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2,12397 2,181.9%   
Profit after tax Rs m10,026702 1,428.0%  
Gross profit margin %28.814.0 206.2%  
Effective tax rate %17.56.9 252.2%   
Net profit margin %18.22.5 735.3%  
BALANCE SHEET DATA
Current assets Rs m48,22824,836 194.2%   
Current liabilities Rs m30,37618,993 159.9%   
Net working cap to sales %32.420.6 157.3%  
Current ratio x1.61.3 121.4%  
Inventory Days Days6871 96.2%  
Debtors Days Days86113 75.4%  
Net fixed assets Rs m64,13034,289 187.0%   
Share capital Rs m3,000895 335.2%   
"Free" reserves Rs m57,98023,651 245.2%   
Net worth Rs m60,98024,546 248.4%   
Long term debt Rs m15,76615,513 101.6%   
Total assets Rs m121,92465,437 186.3%  
Interest coverage x18.11.7 1,056.7%   
Debt to equity ratio x0.30.6 40.9%  
Sales to assets ratio x0.50.4 104.2%   
Return on assets %8.84.1 216.2%  
Return on equity %16.42.9 574.8%  
Return on capital %16.86.9 243.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50615,697 98.8%   
Fx outflow Rs m10,399735 1,414.1%   
Net fx Rs m5,10714,962 34.1%   
CASH FLOW
From Operations Rs m11,5461,871 617.2%  
From Investments Rs m-7,1385,826 -122.5%  
From Financial Activity Rs m-2,417-10,157 23.8%  
Net Cashflow Rs m2,103-2,615 -80.4%  

Share Holding

Indian Promoters % 40.4 27.7 145.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 37.8 22.2%  
FIIs % 10.7 8.6 124.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 25.9 76.8%  
Shareholders   109,995 56,241 195.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  GLENMARK PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 14, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS